Shots:
- GSK has entered into a definitive agreement to acquire RAPT Therapeutics, incl. its P-II asset ozureprubart with data expected in 2027, strengthening GSK’s inflammatory & immunology pipeline
- As per the deal, GSK will acquire RAPT for $58/share, representing the aggregate equity value of $2.2B & an estimated upfront investment of $1.9B cash; closing expected in Q1’26
- Deal will also grant GSK global rights to the ozureprubart program excl. mainland China, Macau, Taiwan & Hong Kong, with GSK assuming responsibility for success-based milestone & royalty payments owed to RAPT’s partner Shanghai Jeyou Pharmaceutical
Ref: GSK | Image: RAPT | Press Release
Related News: RAPT Therapeutics Receives the US FDA’s IND Clearance to Evaluate RPT904 for Food Allergy
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
